Skip to content

Immunome IMNM Total Revenue

Total Revenue at other companies

Pfizer logo
PfizerPFE
$14.45B+5.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$17M-39.3%
Nuvation Bio logo
Nuvation BioNUVB
$83.23M+2,599%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$6.56M
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$44.21M+168%
Exelixis logo
ExelixisEXEL
$610.81M+10.0%

Other financials

Income statement

See full
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.19B+323%
Enterprise value$1.61B+470%
P/S545.2×+498×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunome's total revenue?
Immunome (IMNM) reported total revenue of $0 in Q1 2026.
How has Immunome's total revenue changed year-over-year?
Immunome's total revenue decreased by 100.0% year-over-year, from $2.93M to $0.
What is the long-term trend for Immunome's total revenue?
Over 2 years (2023 to 2025), Immunome's total revenue has grown at a -29.6% compound annual growth rate (CAGR), from $14.02M to $6.94M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.